Johnson & Johnson is buying Guidant Corp., Indianapolis, for about $25.4 billion in cash and stock. J&J said the planned acquisition -- which would be the largest business deal in its 118-year history -- will complement its line of products and services in cardiology and medical devices. J&J owns stentmaker Cordis Corp. Guidant shareholders must approve the deal, under which they would receive $30.40 in cash and $45.60 in J&J stock for each Guidant share. Guidant, a 1994 spin-off by Eli Lilly and Co., capitalized on breakthroughs in heart stents and pacemaker-defibrillator technology to become one of the world's top medical devicemakers. -- by the Associated Press
J&J to buy Guidant in $25.4 billion deal
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.